MicroSPECT/CT imaging and pharmacokinetics of 188Re-(DXR)- liposome in human colorectal adenocarcinoma-bearing mice

Anticancer Research

Volumn 30, Issue 1, 2010, Pages 65-72

  Chen, Min Hua ^a,c   Chang, Chih Hsien ^b   Chang, Ya Jen ^b   Chen, Liang Cheng ^b   Yu, Chia Yu ^b   Wu, Yu Hsien ^b   Lee, Wan Chi ^b   Yeh, Chung Hsin ^b   Lin, Feng Huei ^c   Lee, Te Wei ^b   Yang, Chung Shi ^a   Ting, Gann ^a  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b INSTITUTE OF NUCLEAR ENERGY RESEARCH   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

188Re; Colorectal adenocarcinoma; microSPECT CT imaging; Nanoliposome; Pharmacokinetics

Indexed keywords

LIPOSOME; RHENIUM 188;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CANCER RADIOTHERAPY; COLORECTAL CANCER; DRUG DISTRIBUTION; EXCRETION; FEMALE; IMAGING SYSTEM; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SOLID TUMOR; SPECTROPHOTOMETER; WHOLE BODY AUTORADIOGRAPHY;

ADENOCARCINOMA; ANIMALS; COLORECTAL NEOPLASMS; DOXORUBICIN; HT29 CELLS; HUMANS; LIPOSOMES; MICE; MICE, NUDE; NANOPARTICLES; ORGANOMETALLIC COMPOUNDS; RADIOISOTOPES; RADIOPHARMACEUTICALS; RHENIUM; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TRANSPLANTATION, HETEROLOGOUS;

EID: 77649245577     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T and Thun MJ: Cancer Statistics, 2008. CA Cancer J Clin 58: 71-96, 2008.
2. Liu YC, Sung FC, Hsieh LL, Tang R and Yeh CC: The risk prediction model and risk index for colorectal cancer. Taiwan J Public Health 27: 1-12, 2008.
3. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R and Langer R: Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2: 751-760, 2007.
4. Messerer CL, Ramsay EC, Waterhouse D, Ng R, Simms EM, Harasym N, Tardi P, Mayer LD and Bally MB: Liposomal irinotecan: formulation development and therapeutic assessment in murine xenograft models of colorectal cancer. Clin Cancer Res 10: 6638-6649, 2004.
5. Hamoudeh M, Kamleh MA, Diab R and Fessi H: Radionuclides delivery systems for nuclear imaging and radiotherapy of cancer. Adv Drug Deliv Rev 60: 1329-1346, 2008.
6. Allen TM and Cullis PR: Drug delivery systems: entering the mainstream. Science 303: 1818-1822, 2004.
7. Li SD and Huang L: Pharmacokinetics and biodistribution of nanoparticles. Mol Pharm 5: 496-504, 2008.
8. Alberts DS, Muggia FM, Carmichael J, Winer EP, Jahanzeb M, Venook AP, Skubitz KM, Rivera E, Sparano JA, DiBella NJ, Stewart SJ, Kavanagh JJ and Gabizon AA: Efficacy and safety of liposomal anthracyclines in phase I/II clinical trials. Semin Oncol 31: 53-90, 2004.
9. 188Re-bMEDA-liposome in a C26 murine colon carcinoma solid tumor animal model. Anticancer Res 27: 2217-2225, 2007.
10. Bao A, Goins B, Klipper R, Negrete G and Phillips WT: Direct 99mTc labeling of pegylated liposomal doxorubicin (Doxil) for pharmacokinetic and non-invasive imaging studies. J Pharmacol Exp Ther 308: 419-425, 2004.
11. 186Re-SNS/S complexes: in vitro stability, imaging, and biodistribution in rats. J Nucl Med 44: 1992-1999, 2003.
12. Ogihara-Umeda I, Sasaki T, Kojima S and Nishigori H: Optimal radiolabeled liposomes for tumor imaging. J Nucl Med 37: 326-332, 1996.
13. 188Re-direct labeling of monoclonal antibodies for radioimmunotherapy of solid tumors: biodistribution, normal organ dosimetry, and toxicology. Nucl Med Biol 25: 441-447, 1998.
14. Chen LC, Chang CH, Yu CY, Chang YJ, Hsu WC, Ho CL, Yeh CH, Luo TY, Lee TW and Ting G: Biodistribution, pharmacokinetics and imaging of (188)Re-BMEDA-labeled pegylated liposomes after intraperitoneal injection in a C26 colon carcinoma ascites mouse model. Nucl Med Biol 34: 415-423, 2007.
15. Choy H and Kim DW: Chemotherapy and irradiation interaction. Semin Oncol 30: 3-10, 2003.
16. Huber PE, Bischof M, Jenne J, Heiland S, Peschke P, Saffrich R, Grone HJ, Debus J, Lipson KE and Abdollahi A: Trimodal cancer treatment: beneficial effects of combined antiangiogenesis, radiation, and chemotherapy. Cancer Res 65: 3643-3655, 2005.
17. Barbara Haley EF: Nanoparticles for drug delivery in cancer treatment. Urologic Oncology: Seminars and Original Investigations 26: 57-64, 2008.
18. 188Re-(DXR) - liposome for internal radiotherapy. Cancer Biotherapy and Radiopharmaceuticals 23: 749-758, 2008.
19. Chen LC, Chang CH, Yu CY, Chang YJ, Wu YH, Lee WC, Yeh CH, Lee TW and Ting G: Pharmacokinetics, micro-SPECT/CT imaging and therapeutic efficacy of (188)Re-DXR-liposome in C26 colon carcinoma ascites mice model. Nucl Med Biol 35: 883-893, 2008.
20. Carlson SK, Classic KL, Hadac EM, Bender CE, Kemp BJ, Lowe VJ, Hoskin TL and Russell SJ: In vivo quantitation of intratumoral radioisotope uptake using micro-single photon-emission computed tomography/computed tomography. Mol Imaging Biol 8: 324-332, 2006.
21. 111In-VNB-liposome on human colorectal adenocarcinoma HT-29/luc mouse xenografts. Nucl Instrum Methods Phys Res Sect A 569: 497-504, 2006.
22. Tseng YL, Hong RL, Tao MH and Chang FH: Sterically stabilized anti-idiotype immunoliposomes improve the therapeutic efficacy of doxorubicin in a murine B-cell lymphoma model. Int J Cancer 80: 723-730, 1999.
23. Bartlett GR: Phosphorus assay in column chromatography. J Biol Chem 234: 466-468, 1959.
24. 188Re generators. Appl Radiat Isot 47: 23-26, 1996.
25. Tilcock C: Delivery of contrast agents for magnetic resonance imaging, computed tomography, nuclear medicine and ultrasound. Adv Drug Deliv Rev 37: 33-51, 1999.
26. Gabizon A, Catane R, Uziely B, Kaufman B, Safra T, Cohen R, Martin F, Huang A and Barenholz Y: Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 54: 987-992, 1994.
27. Alexis F, Rhee JW, Richie JP, Radovic-Moreno AF, Langer R and Farokhzad OC: New frontiers in nanotechnology for cancer treatment. Urol Oncol 26: 74-85, 2008.
28. Ting G, Chang CH and Wang HE: Cancer nanotargeted radiopharmaceuticals for tumor imaging and therapy. Anticancer Res 29: 4107-4118, 2009.
29. Phillips WT, Goins B and Bao A: Radioactive liposomes. Wiley Interdiscipl Rev Nanomed Nanobiotechnol 1: 69-83, 2009.
30. Chow TH, Lin YY, Hwang JJ, Wang HE, Tseng YL, Pang VF, Wang SJ, Whang-Peng J and Ting G: Diagnostic and therapeutic evaluation of (111)In-vinorelbine-liposomes in a human colorectal carcinoma HT-29/luc-bearing animal model. Nucl Med Biol 35: 623-634, 2008.
31. Goins BA: Radiolabeled lipid nanoparticles for diagnostic imaging. Expert Opin Med Diagn 2: 853-873, 2008.
32. Park JW, Kirpotin DB, Hong K, Shalaby R, Shao Y, Nielsen UB, Marks JD, Papahadjopoulos D and Benz CC: Tumor targeting using anti-her2 immunoliposomes. J Control Release 74: 95-113, 2001.
33. Chow TH, Lin YY, Hwang JJ, Wang HE, Tseng YL, Wang SJ, Liu RS, Lin WJ, Yang CS and Ting G: Improvement of biodistribution and therapeutic index via increase of polyethylene glycol on drug-carrying liposomes in an HT-29/luc xenografted mouse model. Anticancer Res 29: 2111-2120, 2009.